You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT JAMA
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 282 No. 2, July 14, 1999 TABLE OF CONTENTS
  JAMA
  •  Online Features
  Editorial
 This Article
 •Full text
 •PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on ISI (11)
 •Contact me when this article is cited
 Related Content
 •Similar articles in JAMA

Intranasal Influenza Vaccine

Adding to the Armamentarium for Influenza Control

Gregory A. Poland, MD; Robert Couch, MD

JAMA. 1999;282:182-184.

Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

In the United States, national influenza vaccine recommendations have typically been based on the prevention of complications and death among high-risk persons. More recent is the increasing awareness that above and beyond the more severe individual medical consequences of influenza, enormous societal economic costs are associated with disruptions due to school and work absences and days of illness. In this issue of THE JOURNAL, Nichol et al1 report that use of a live, attenuated influenza virus (LAIV) vaccine, administered by intranasal spray to healthy, working adults (a group without a routine recommendation to receive influenza vaccine), was followed in the subsequent influenza epidemic season by a significant reduction in severe febrile illness, days lost from work, health care visits, and the medication use that accompanies these illnesses. Are these findings important? From an individual, medical, and public health point of view, the answer . . . [Full Text of this Article]

Author Affiliations: Clinical Pharmacology and Mayo Vaccine Research Group, Mayo Medical School and Foundation, Rochester, Minn (Dr Poland); and Department of Microbiology and Immunology, Baylor College of Medicine, Houston, Tex (Dr Couch).



THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Influenza Vaccination Trends Among Adults 65 Years or Older in the United States, 1989-2002
Lu et al.
Arch Intern Med 2005;165:1849-1856.
ABSTRACT | FULL TEXT  

Routine influenza vaccination for healthy children---old concept, new technologies
BEYER
Arch. Dis. Child. 2000;83:461-462.
FULL TEXT  

Live Intranasal Influenza Vaccine Protects Healthy Adults
JWatch Infect. Diseases 1999;1999:13-13.
FULL TEXT  

Intranasal Flu Vaccine Effective in Adults
JWatch General 1999;1999:3-3.
FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1999 American Medical Association. All Rights Reserved.